Agency of the United States Department of Health and Human Services
POPULARITY
Categories
357 episodes with fda
281 episodes with fda
183 episodes with fda
247 episodes with fda
229 episodes with fda
126 episodes with fda
183 episodes with fda
112 episodes with fda
147 episodes with fda
150 episodes with fda
273 episodes with fda
183 episodes with fda
178 episodes with fda
185 episodes with fda
53 episodes with fda
82 episodes with fda
75 episodes with fda
90 episodes with fda
65 episodes with fda
62 episodes with fda
135 episodes with fda
55 episodes with fda
70 episodes with fda
107 episodes with fda
107 episodes with fda
61 episodes with fda
68 episodes with fda
36 episodes with fda
96 episodes with fda
44 episodes with fda
50 episodes with fda
65 episodes with fda
44 episodes with fda
42 episodes with fda
105 episodes with fda
43 episodes with fda
64 episodes with fda
50 episodes with fda
47 episodes with fda
51 episodes with fda
61 episodes with fda
97 episodes with fda
78 episodes with fda
41 episodes with fda
38 episodes with fda
59 episodes with fda
64 episodes with fda
56 episodes with fda
55 episodes with fda
97 episodes with fda
73 episodes with fda
59 episodes with fda
49 episodes with fda
99 episodes with fda
Brigham Buhler is a healthcare entrepreneur transforming America's broken system. As founder of Ways2Well, owner of Revive Rx Pharmacy, and an investor in psychedelic research, he champions a model of care that prioritizes patients over profits through preventative medicine, transparency, and innovation. His work is guided by a few core convictions: -Former insider's perspective: With deep experience navigating the corrupt systems of pharmacy benefit managers (PBMs), insurance companies, and the FDA, Brigham knows firsthand how the system is stacked against patients. -Uncompromising advocate: He pushes to expose and dismantle the corporate capture of American healthcare. -Bold truth-teller: He believes in revealing the realities of the insurance Ponzi scheme and providing practical ways to bypass outdated systems. -Relentless reformer: He is dedicated to replacing a model that profits off sickness with one centered on health, longevity, and patient empowerment. Today's Sponsors: Black Rifle Coffee: https://www.blackriflecoffee.com LMNT: https://www.drinklmnt.com/clearedhot
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter addresses the recent headlines linking acetaminophen (Tylenol) use during pregnancy to autism in exposed children. Recognizing the confusion these claims have sparked among patients, listeners, and the broader public, Peter uses this episode to provide a framework for thinking critically about complex conditions and the research related to them. He highlights the dramatic rise in autism diagnoses over recent decades, noting that multifactorial conditions rarely have a single cause, and emphasizes the importance of resisting oversimplified explanations. Peter also stresses that humans are not naturally wired for scientific thinking, making disciplined frameworks like the Bradford Hill criteria essential for evaluating causality in epidemiology. Ultimately, he uses this framework to explore the evidence surrounding acetaminophen use during pregnancy and its potential link to autism. We discuss: Laying the groundwork for this discussion, the rise in autism rates, and the value in using frameworks [1:00]; The FDA pregnancy drug categories, where Tylenol falls within that framework, and a structured method for evaluating scientific evidence and causality [6:00]; What exactly are the claims being made about acetaminophen and autism? [13:45]; The increase in autism rates and why so many things are being linked to autism: the multiple comparisons problem [15:00]; Evaluating the review paper that triggered the recent concern over acetaminophen and autism [21:45]; Breaking down the largest studies on prenatal Tylenol exposure and autism: is there a causal link? [35:00]; Why observational studies can't prove causality, the role of confounding variables, and the importance of frameworks like the Bradford Hill criteria [43:30]; Applying the Bradford Hill criteria: testing the case for Tylenol and autism [45:45]; Putting it all together to answer the question: Does acetaminophen use during pregnancy increase the risk of autism? [56:15]; If autism risk is overwhelmingly genetic, what explains the dramatic rise in autism diagnoses? [59:15]; Other risk factors for autism: parental age, maternal health, environment, and where Tylenol fits in [1:09:15]; Medication use during pregnancy: balancing risks, benefits, and FDA categories [1:15:15]; Considerations for taking Tylenol during pregnancy [1:19:30]; Final thoughts: critical thinking, balanced risk assessment, and the importance of context when evaluating medications like Tylenol during pregnancy [1:22:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
Our conversation today is on the recent FDA panel about the safety of antidepressants during pregnancy—and all the ways the panel got it wrong. It's not just about wrong information, but it's about the harm that wrong information does to people in the perinatal period. Join us to learn more about why this information from the FDA is so dangerous to women. Dr. Catherine Birndorf is a reproductive psychiatrist and the CEO, founder, and medical director of The Motherhood Center of New York. Dr. Birndorf is a founding director of the Payne Whitney Women's Program at Weill Cornell Medical Center at New York-Presbyterian Hospital, where she is a clinical associate professor of psychiatry. A graduate of Smith College, Dr. Birndorf attended Brown University Medical School and did her psychiatry residency at New York-Presbyterian Hospital. For 10 years, Dr. Birndorf was a regular mental health columnist for Self Magazine and appeared on numerous television programs, including the Today Show, Good Morning America, MSNBC, and CNN. Her most recent book, What No One Tells You: A Guide to Your Emotions from Pregnancy to Motherhood, was published by Simon & Schuster in 2019. Show Highlights: Dr. Birndorf's perspective on the FDA panel and their decisions: “I knew this was a disaster in the making.” The FDA panel was made up of 10 “experts” (8 men/2 women) who were biased and stacked against medication and mental illness. Women have been suffering, and they continue to suffer. The work of The Motherhood Center in supporting women who need help through mental illness The potential for harm is HUGE. What Dr. Birndorf wants people to know about mental illness and life-saving medications Dr. Birndorf's motivation to start The Motherhood Center Highlights of the support provided for women through The Motherhood Center The ways we “mother” have impacts on the generations to come; no mother should suffer with mental illness when transformation is possible. The Motherhood Center focuses on all the therapies and interventions that bring wellness, not just medications. Resources: Connect with Dr. Catherine Birndorf: Website, Instagram, Facebook, and What No One Tells You: A Guide to Your Emotions from Pregnancy to Motherhood Call the National Maternal Mental Health Hotline at 1-833-TLC-MAMA or visitcdph.ca.gov. Please find resources in English and Spanish at Postpartum Support International, or by phone/text at 1-800-944-4773. There are many free resources, like online support groups, peer mentors, a specialist provider directory, and perinatal mental health training for therapists, physicians, nurses, doulas, and anyone who wants to be more supportive in offering services. You can also follow PSI on social media, including Instagram, Facebook, and other platforms. Visit www.postpartum.net/professionals/certificate-trainings/for information on the grief course. Visit my website, www.wellmindperinatal.com, for more information, resources, and courses you can take today! If you are a California resident seeking a therapist in perinatal mental health, please email me about openings for private pay clients. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Happy Q4 Heart of Healthcare Listeners! We're back with your monthly Digital Health Download, where we discuss the biggest industry headlines of the month. We cover:
What happens when binge eating disorder and bipolar disorder collide? Research shows they co-occur in as many as one in four cases — and yet, many people living with both conditions feel completely alone. In this episode, host Gabe Howard shares his personal journey of living with bipolar disorder and binge eating disorder, including how food was his form of self-medication.Board certified psychiatrist Dr. Nicole Washington breaks down the clinical side: what binge eating disorder actually is, how it's diagnosed, and why treating it alongside bipolar disorder can get “tricky.” Listeners will learn: signs and symptoms of binge eating disorder (beyond overeating) why stability with bipolar disorder often makes binge eating easier to manage unique treatment challenges — including why the only FDA-approved medication for binge eating disorder may be destabilizing for people living with bipolar disorder Gabe and Dr. Nicole rip the lid off the shame, secrecy, and stigma surrounding binge eating disorder, especially when it coincides with bipolar disorder. With honesty and compassion, they share practical treatment insights, real hope, and a powerful reminder: You are not alone. Whether you're having trouble or supporting someone you love, this episode delivers validation, guidance, and the encouragement you need to take the next step toward healing and living your best life. "I weighed over 550 pounds and I knew that I was unhealthy. But I didn't really see binge eating disorder as a mental health problem because bipolar disorder sucked all the oxygen out of the room. And I was lucky, I did go from over 550 pounds down to the 200 that I weigh now, because I had the right interventions. I treated both bipolar disorder and binge eating disorder. But I imagine that many listeners, they don't realize the connection between these two." ~Gabe Howard, Host Our host, Gabe Howard, is an award-winning podcast host, author, and sought-after suicide prevention and mental health speaker, but he wouldn't be any of those things today if he hadn't been committed to a psychiatric hospital in 2003.Gabe also hosts Healthline's Inside Mental Health podcast has appeared in numerous publications, including Bipolar magazine, WebMD, Newsweek, and the Stanford Online Medical Journal. He has appeared on all four major TV networks, ABC, NBC, CBS, and FOX. Among his many awards, he is the recipient of Mental Health America's Norman Guitry Award, received two Webby Honoree acknowledgements, and received an official resolution from the Governor of Ohio naming him an “Everyday Hero.” Gabe wrote the popular book, "Mental Illness is an Asshole and other Observations," available from Amazon; signed copies are available directly from the author with free swag included! To learn more about Gabe, or to book him for your next event, please visit his website, gabehoward.com. Our host, Dr. Nicole Washington, is a native of Baton Rouge, Louisiana, where she attended Southern University and A&M College. After receiving her BS degree, she moved to Tulsa, Oklahoma to enroll in the Oklahoma State University College of Osteopathic Medicine. She completed a residency in psychiatry at the University of Oklahoma in Tulsa. Since completing her residency training, Dr. Nicole has spent most of her career caring for and being an advocate for those who are not typically consumers of mental health services, namely underserved communities, those with severe mental health conditions, and high performing professionals. Through her private practice, podcast, speaking, and writing, she seeks to provide education to decrease the stigma associated with psychiatric conditions. Find out more at DrNicolePsych.com. Learn more about your ad choices. Visit megaphone.fm/adchoices
Essential oils are concentrated plant extracts obtained through distillation and pressing. This process captures the aromatic compounds responsible for the oils' fragrance and therapeutic effects The U.S. Food and Drug Administration (FDA) designates some oils as Generally Recognized as Safe (GRAS), meaning food-grade oils are safe to ingest in tiny amounts GRAS essential oils like peppermint, lemon, ginger, cinnamon, and basil can be used to flavor foods and beverages. This reflects their culinary value when used sparingly Other essential oils, such as lavender, eucalyptus, tea tree, rosemary, chamomile, wintergreen, and camphor, are best suited for aromatic or topical use Whether in food, through scent, or applied to the skin, essential oils support wellness when used with care and intention
On this episode of Vitality Radio, Jared sits down with Dr. Jason Klop, founder of Novel Biome, to explore one of the most fascinating and misunderstood frontiers in health: fecal microbiota transplant (FMT). Often misnamed “fecal matter transplant,” FMT is a highly purified process that restores microbial diversity in the gut—far beyond what probiotics alone can achieve. Jared and Dr. Klop discuss why FMT is gaining traction in digestive health, neurological conditions, and immune balance, and how it differs from traditional probiotic supplementation. You'll learn about the rigorous donor screening process, oral vs. rectal delivery methods, and why gut microbiome diversity is critical for overall vitality. The potential applications of FMT are broad and promising. This conversation pulls back the curtain on how supporting the gut ecosystem could impact everything from digestion and inflammation to mood and longevity.Additional Information:Novel BiomeNovel Biome - InstagramPodcast – Biome Breakthroughs (Spotify): Listen hereVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
I had such a powerful and eye-opening conversation with Lisa Curtis, Founder & CEO of Kuli Kuli Foods. Lisa shared her incredible journey that began in the Peace Corps in Niger, where she first discovered moringa, a nutrient-packed “tree leaf” that transformed her health. What started as a simple act of self-care in a rural village has grown into Kuli Kuli Foods, a pioneering superfoods brand that now partners with thousands of small farmers across Africa and India, empowers women, and brings nutritious, climate-smart foods to shelves nationwide. Lisa opened up about the early hurdles, navigating FDA approvals, raising money through crowdfunding, and hustling at farmers' markets, and how those small proof points led to partnerships with Whole Foods, Walmart, and more. We also explored the resilience it takes to keep going for over 12 years, her gratitude practice, and the leadership lessons that continue to guide her. This episode is packed with inspiration for entrepreneurs and food lovers alike. Here are some highlights from our conversation: How a Peace Corps experience in Niger led to the discovery of moringa and sparked the founding of Kuli Kuli Foods. Overcoming early supply chain and regulatory challenges, including a $70,000 FDA hurdle with creativity and mentorship. The role of farmers' markets and crowdfunding in proving demand and landing Whole Foods as their first big customer. Building impact by partnering with 3,000 small farmers and reinvesting 10% of profits into community projects worldwide. Lisa's advice for entrepreneurs: map out small proof points, celebrate wins, and keep the courage to start and persist. Join me, Ramon Vela, as I listen to Lisa's inspiring story of grit, gratitude, and global impact, and to discover how Kuli Kuli is changing the way we think about superfoods. For more on Kuli Kuli Foods, visit: https://www.kulikulifoods.com/ If you enjoyed this episode, please leave The Story of a Brand Show a rating and review. Plus, don't forget to follow us on Apple and Spotify. Your support helps us bring you more content like this! * Today's Sponsors: REViVE Amazon Marketing Partners: https://revivemp.com/ REViVE Amazon Marketing Partners helps better-for-you CPG brands win on Amazon with niche expertise, founder-led strategy, and a true partnership model. Built by a CPG founder with a successful exit, REViVE only works with brands it believes in. Are you curious if Amazon is right for you? Book a Free Deep Dive Strategy Session today. Workspace6 - Private Community for 7, 8, 9-figure Brands: https://www.workspace6.io/ Workspace6 is a private community where over 950 seven-, eight-, and nine-figure brand operators share insights, solve problems, and accelerate growth. It's the anti-fluff operator's room, and for your first 30 days, it's just $1. Get real answers and skip the trial and error.
X: @GarrettInExile @americasrt1776 @ileaderssummit @NatashaSrdoc @JoelAnandUSA @supertalk Join America's Roundtable (https://americasrt.com/) radio co-hosts Natasha Srdoc and Joel Anand Samy with the Honorable Tom Garrett, a leading attorney, currently serving as a legislator in the Commonwealth of Virginia, former Assistant Attorney General and former U.S. Congressman. While serving in the US Congress, Tom served on the Foreign Affairs Committee and Homeland Security Committee. An expert on Iran and the Middle East, Tom Garrett's analysis and insights are enlightening as America's foreign policy and national security concerns are focused on a strategic region adversely impacted by Iran, a state sponsor of terrorism. Key Topics: The state of America's economy and the impact of the One Big Beautiful Bill Act focused on cutting taxes for everyday and hardworking Americans, including no tax on tips and overtime, no tax on social security, and savings for American families. Energy | Fuel costs going down with a goal to make America energy independent. President Trump's speech at the United Nations and the truth that while Western nations spend hundreds of billion of taxpayer dollars on the efforts to address climate change while China continues to be the world's number polluter. He called it "a conjob." President Trump stated that renewable energy, along with migration, was destroying Western countries and placing nations in debt and added greater security challenges. Published report: _President Trump attacked global immigration and efforts to fight climate change during an address to the United Nations, claiming they were among the world's top threats to Western civilization. In an hour-long speech filled with grievances about ongoing wars, windmills and malfunctioning escalators, it was Trump's attacks against what he called a “double-tailed monster” that rang loudest in the ornate General Assembly room. “Immigration and the high cost of so-called green, renewable energy is destroying a large part of the free world and a large part of our planet,” he said. “Countries that cherish freedom are fading fast because of their policies on these two subjects. Both immigration and their suicidal energy ideas will be the death of Western Europe.” “I'm telling you that if you don't get away from the ‘green energy' scam, your country is going to fail. If you don't stop people that you've never seen before that you have nothing in common with, your country is going to fail.” _ President Donald Trump, speech delivered at the United Nations, September 23, 2025 America's eyes are focused on state-wide elections in New Jersey and Virginia, with governors' races and the legislatures which will determine key policies including economic and social issues. Pro-life advocates are concerned about Virginian Democrats pushing for a radical plan: House Joint Resolution 1/Senate Joint Resolution 247, would amend the Virginia Constitution to allow for unrestricted abortion through the third trimester of pregnancy – repealing and preventing widely supported abortion regulations that enjoy broad support from the American people. New manufacturing plant in the United States - Insulin for Americans | Competition to bring down prices of pharmaceuticals in America | India's Biocon which produces biosimilars and insulin opened its first manufacturing facility in New Jersey. Biocon Biologics is a global leader in biosimilars and insulin production and is among the top three global players for rh-Insulin and Insulin Glargine, providing over 9.2 billion doses of insulin globally with a broad portfolio comprising basal, mixed and rapid acting insulins. Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said, “Biocon's first U.S. FDA approved formulations facility in New Jersey marks a new chapter in our journey of global expansion. More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are." Washington Times, op-ed by Natasha Srdoc and Joel Anand Samy: FDA must fast track insulin for the millions of Americans living with diabetes https://www.washingtontimes.com/news/2019/oct/17/fda-must-fast-track-insulin-for-the-millions-of-am/ Bio | Tom Garrett Virginia Delegate Tom Garrett earned his Bachelor's degree from the University of Richmond. After the University of Richmond, Tom Garrett became an artillery officer in the United States Army. Achieving the rank of Captain, Tom led soldiers overseas—most notably while deployed in Bosnia. Upon returning to the States, Tom earned his J.D. from the University of Richmond and quickly became an Assistant Attorney General for Virginia. In 2016, Tom was elected to represent Virginia's 5th Congressional District in the United States House of Representatives. Tom won that election with the most votes ever in the 5th Congressional District. While in Congress, Tom served on the Foreign Affairs Committee, Homeland Security Committee, Education and Workforce Committee and was a member of the Freedom Caucus. In the years since, Tom Garrett has dedicated his life to fighting for the oppressed and forgotten not only here in America, but around the world. Tom has been working on a global docu-series project, Exile, (https://www.wvtf.org/news/2021-12-10/former-congressman-tom-garrett-working-on-a-new-documentary-series) which tells the untold stories of those who are persecuted based on their faith or ethnicity. In addition to continuing his work as a defense attorney, Tom has served as a consultant and most recently, cofounder for firms working in global energy development. americasrt.com (https://americasrt.com/) https://summitleadersusa.com/ | https://jerusalemleaderssummit.com/ America's Roundtable on Apple Podcasts: https://podcasts.apple.com/us/podcast/americas-roundtable/id1518878472 X: @GarrettInExile @americasrt1776 @ileaderssummit @NatashaSrdoc @JoelAnandUSA @supertalk America's Roundtable is co-hosted by Natasha Srdoc and Joel Anand Samy, co-founders of International Leaders Summit and the Jerusalem Leaders Summit. America's Roundtable (https://americasrt.com/) radio program focuses on America's economy, healthcare reform, rule of law, security and trade, and its strategic partnership with rule of law nations around the world. The radio program features high-ranking US administration officials, cabinet members, members of Congress, state government officials, distinguished diplomats, business and media leaders and influential thinkers from around the world. Tune into America's Roundtable Radio program from Washington, DC via live streaming on Saturday mornings via 68 radio stations at 7:30 A.M. (ET) on Lanser Broadcasting Corporation covering the Michigan and the Midwest market, and at 7:30 A.M. (CT) on SuperTalk Mississippi — SuperTalk.FM reaching listeners in every county within the State of Mississippi, and neighboring states in the South including Alabama, Arkansas, Louisiana and Tennessee. Tune into WTON in Central Virginia on Sunday mornings at 6:00 A.M. (ET). Listen to America's Roundtable on digital platforms including Apple Podcasts, Spotify, Amazon, Google and other key online platforms. Listen live, Saturdays at 7:30 A.M. (CT) on SuperTalk | https://www.supertalk.fm
This episode is sponsored by BetterHelp. Give online therapy a try at BetterHelp. Give online therapy a try at https://betterhelp.com/damagereport and get on your way to being your best self. A Republican candidate allegedly posted Nazi-themed porn. Trump's former spiritual advisor pleads guilty to child sexual assault. Americans are blaming republicans for the shutdown. ICE is using a new tool to watch millions of people. Conservatives are furious with the FDA. MAGA slams a Charlie Kirk protege after a private jet video emerges Host: John Iadarola (@johniadarola) Co-Host: Brett Erlich (@bretterlich) ***** SUBSCRIBE on YOUTUBE TIKTOK ☞ https://www.tiktok.com/@thedamagereport INSTAGRAM ☞ https://www.instagram.com/thedamagereport TWITTER ☞ https://twitter.com/TheDamageReport FACEBOOK ☞ https://www.facebook.com/TheDamageReportTYT
SPONSOR: RELIEFBAND - If you deal with nausea, Reliefband is a breakthrough you need to know about. It’s the original anti-nausea wristband that quickly relieves and effectively prevents nausea and vomiting, without the use of drugs or drowsy side effects. You simply wear it on your wrist, adjust the intensity depending on how you’re feeling, and within minutes, it starts working. The new Premier Plus model even includes a digital clock and smart skin-sensing technology to help preserve battery life. It’s FDA-cleared technology originally developed for hospital use. So, if you want to cure your nausea problem FAST, join the hundreds of thousands of people who are nausea-free with Reliefband. Right now, there’s an exclusive offer just for listeners of the Rick Burgess Show. If you go to http://www.Reliefband.com and use promo code “RICKB” you’ll receive 20% off, plus free shipping!See omnystudio.com/listener for privacy information.
SPONSOR: RELIEFBAND - If you deal with nausea, Reliefband is a breakthrough you need to know about. It’s the original anti-nausea wristband that quickly relieves and effectively prevents nausea and vomiting, without the use of drugs or drowsy side effects. You simply wear it on your wrist, adjust the intensity depending on how you’re feeling, and within minutes, it starts working. The new Premier Plus model even includes a digital clock and smart skin-sensing technology to help preserve battery life. It’s FDA-cleared technology originally developed for hospital use.So, if you want to cure your nausea problem FAST, join the hundreds of thousands of people who are nausea-free with Reliefband. Right now, there’s an exclusive offer just for listeners of the Rick Burgess Show. If you go to http://www.Reliefband.com and use promo code “RICKB” you’ll receive 20% off, plus free shipping!See omnystudio.com/listener for privacy information.
Today's Headlines: President Trump has formally declared the U.S. to be in an “armed conflict” with drug cartels, invoking war powers and ordering military strikes on Caribbean boats the administration labels as “terrorist organizations.” Lawmakers in both parties are skeptical of the legal basis but—shocker—seem unlikely to act. Meanwhile, the government shutdown has left 750,000 workers unpaid or furloughed, and the White House is now threatening permanent firings with help from Project 2025 architect Russell Vought. Shutdown propaganda even seeped into federal employees' auto-replies, which were forcibly edited to blame Democrats. The Energy Department axed $7.6 billion in clean energy grants, conveniently targeting states that voted for Kamala Harris. The administration also sent nine universities—including Vanderbilt, MIT, and Brown—a “compact” demanding they overhaul admissions, freeze tuition, and abolish certain departments in exchange for federal funds. Elsewhere, the FDA approved a generic version of the abortion pill mifepristone, sparking predictable outrage despite it being a routine process. Yom Kippur was marred by a deadly terror attack at a synagogue in Manchester, where two worshippers were killed and the attacker was shot dead. And finally, Commerce Secretary Howard “Laughin'” Lutnick, a former neighbor of Jeffrey Epstein, suggested Epstein blackmailed powerful men with videos, casually detonating months of damage control efforts with a single podcast appearance. Resources/Articles mentioned in this episode: AP News: Trump says US is in 'armed conflict' with drug cartels after ordering strikes in the Caribbean WSJ: Lawmakers From Both Sides Pressed Pentagon on Legal Basis for Cartel Boat Strikes Axios: Trump embraces Project 2025 after disavowing it during 2024 campaign Wired: Government Workers Say Their Out-of-Office Replies Were Forcibly Changed to Blame Democrats for Shutdown AP News: Trump administration cuts nearly $8B in clean energy projects in states that backed Harris WSJ: Exclusive | Trump White House Asks Colleges to Sign Sweeping Agreement to Get Funding Advantage AP News: FDA approves another generic abortion pill, prompting outrage from conservatives Reuters: Synagogue attack on Yom Kippur kills two in UK's Manchester; suspect shot dead ABC News: Howard Lutnick believes Jeffrey Epstein may have used blackmail to get a lighter sentence Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices
The news to know for Friday, October 3, 2025! We'll tell you where President Trump is promising to make permanent cuts during this government shutdown. Also, we're talking about a new notice telling Congress the U.S. is at war with drug cartels. And the backlash over a new abortion pill that just got the FDA's approval. Plus: the latest records broken on Wall Street, the reason many conservatives are quitting Netflix, and the frenzy over Taylor Swift's newest album that came out overnight. Those stories and even more news to know in about 10 minutes! Join us every Mon-Fri for more daily news roundups! See sources: https://www.theNewsWorthy.com/shownotes Become an INSIDER to get AD-FREE episodes here: https://www.theNewsWorthy.com/insider Sign-up for our Friday EMAIL here: https://www.theNewsWorthy.com/email Get The NewsWorthy MERCH here: https://thenewsworthy.dashery.com/ Sponsors: Get 50% off 1 month of Trade at drinktrade.com/newsworthy Save 25% on your first month of a Dose subscription by going to dosedaily.co/NEWSWORTHY or entering NEWSWORTHY at checkout. To advertise on our podcast, please reach out to ad-sales@libsyn.com
Our China Healthcare Analyst Jack Lin discusses how China's biotech surge is reshaping healthcare, investment and innovation worldwide.Read more insights from Morgan Stanley.----- Transcript ----- Jack Lin: Welcome to Thoughts on the Market. I'm Jack Lin, from Morgan Stanley's China Healthcare Team. Today, the boom in China biotech – and how it's not just a headline for China-focused investors, but a story that touches all of us. It is Friday, October 3rd at 2pm in Hong Kong. Many people might not realize this but some of the next generation healthcare innovation is being developed far from Silicon Valley and Wall Street. The medicines you rely on, treatment plans that could shape your family's future, even investment opportunity that can grow your savings. They are all increasingly influenced by China's rapidly evolving biotech sector, which is transitioning from traditional generics manufacturing into the global innovation ecosystem. In fact, China's biotech industry is set to become a major player in the global innovation ecosystem. By 2040, we project China's originated assets could represent about a third of U.S. FDA approvals – up dramatically from just 5 percent today. And the question isn't if China's biotech will matter, but how global patients could benefit; and how consumers and investors worldwide might engage with its impact.What's driving this transformation? Three key components are driving the globalization of China originated drug innovations: cost, accessibility, and innovation quality. Lower cost in China's biotech sector enables more efficient development. Clinical trial quality is improving with regulatory pathways becoming more streamlined, promoting accessibility of China innovation for global markets. Finally, innovation in China's biotech sector is gaining momentum with more regionally developed medicines now eyeing market approval from leading overseas agencies like the U.S. FDA and EMA.This is all to say China is on track to become a key force on the global biotech stage. That said, right now we're also at a crossroads moment as geopolitical tensions between U.S. and China pose potential risks to the flow of innovation. Despite these uncertainties, we see a likely outcome of co-opetition, a blend of competition and collaboration, as global pharma grapples with the dual imperatives of innovation and resilience. Of course, this rapid evolution brings both opportunities and challenges. It's prompting stakeholders around the world to rethink their strategies and collaborations in this shifting landscape of global medical innovation. As the China biotech industry evolves, the choices made by investors, policy makers, and healthcare communities, both within China and globally, will determine the therapies of the future. It is truly a dynamic space, and we'll continue to bring you updates. Thanks for listening to our thoughts on the market. If you enjoy the show, please leave us a review, wherever you listen and share Thoughts on the Market with a friend or colleagues today.
Aaron McIntire dives into the week's top stories on The A.M. Update, covering the government shutdown debate, Democrats' push for healthcare for illegal immigrants, a shocking anti-Semitic attack in the UK, more on that bizarre Iowa superintendent case, and the FDA's approval of a generic abortion pill. Plus, listener questions in Ask or Tell Me Anything tackle military leadership, church engagement, and eschatology. government shutdown, immigration, healthcare, anti-Semitism, UK attack, Iowa superintendent, abortion pill, FDA, Project 2025, Trump, listener questions,
The federal government has frozen funds to another Democrat run city as the government shutdown continues. Sean “Diddy” Combs is set for a lengthy sentencing hearing today. President Donald Trump has given a stark ultimatum to Hamas over his Gaza peace proposal. The shutdown has stopped the jobs report coming out today, but other data has given an estimate on job numbers. Plus, why abortion opponents are angry at the FDA. Learn more about your ad choices. Visit podcastchoices.com/adchoices
D.C. insider Tom McClusky takes us behind the scenes of the government shutdown—what's really happening in Washington? Meanwhile, the FDA approves a new abortion drug, sparking outrage and debate. And finally, Erika gives her take on Pope Leo's ice block blessing. All this and more on the LOOPcast!00:00 Welcome to the LOOPcast 02:00 Nazareth Organics04:18 GOV Shutdown Day 3 Update 20:02 Home Title Lock27:54 Good News39:20 Gaza Peace Plan1:00:00 Twilight Zone1:09:45 Closing PrayerNazareth Organics is a Catholic family-owned natural skincare company that handcrafts tallow balms and serums with high-quality, wild-crafted, and organic ingredients. Find them at https://nazareth-organics.com and use code LOOPCAST at checkout for a 10% discount. Follow them on Instagram and Facebook at: @nazarethorganicsProtect your equity with Home Title Lock's exclusive Million Dollar Triple Lock Protection, now for just $1 for 60 days when you use promocode LOOP60! Click here: https://www.hometitlelock.com/looper to learn more!EMAIL US: loopcast@catholicvote.org SUPPORT LOOPCAST: www.loopcast.orgSubscribe to the LOOP today!https://catholicvote.org/getloop Apple Podcasts: https://podcasts.apple.com/us/podcast/the-loopcast/id1643967065 Spotify: https://open.spotify.com/show/08jykZi86H7jKNFLbSesjk?si=ztBTHenFR-6VuegOlklE_w&nd=1&dlsi=bddf79da68c34744 FOLLOW LOOPCast: https://x.com/the_LOOPcast Tom: https://x.com/TPogasic Erika: https://x.com/ErikaAhern2 Josh: https://x.com/joshuamercer All opinions expressed on LOOPcast by the participants are their own and do not necessarily reflect the opinions of CatholicVote.
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels. Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said. “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.” Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas. The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/ XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition. G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment. The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes. "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes. The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.). – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November. https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/ XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. , The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say. In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries." The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours. Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy. At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy. Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells. Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially. Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells. “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release. “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification
This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338
Hour 1 for 10/3/25 Guest-host Ed Morrissey and Abby Johnson discuss the recent FDA approval of a generic abortion drug (3:17), pharma ads (11:37), and an attack on women (15:23). Then, Anthony Kolton covers his company working on a cure for juvenile diabetes (27:37). Finally, Matthew Haas discussing supporting future priests (41:05). Links: https://www.regenmedsolutions.com/about/leadership-team/ https://futureshepherds.org/ x.com/abbyjohnson
As Dalton sat in for Jim Schneider, here's a selection of stories he presented for the first half of the broadcast: --Last Sunday at least 4 victims died and multiple people were injured during a shooting at a Church of Jesus Christ of Latter Day Saints in Michigan. The assailant drove their vehicle through the front doors of the building, then got out and proceeded to shoot people. That suspect was later killed in a firefight with police. --A synagogue attack on Yom Kippur killed 2 in Manchester, England. --The U.N. added 68 companies to a blacklist they maintain are firms that do business with Jewish communities in Judea and Samaria. --Dalton read 9 signs that the world is preparing for war from Charisma Magazine. --Vladimir Putin has ordered the conscription of over 135,000 men by the end of 2025. --The FDA approved a new generic version of the abortion drug Mifepristone. --Planned Parenthood announced that their facility in Houston, Texas, the largest abortion facility in North America, is closing down.
Today's show is sponsored by: Peraton Peraton is a company that has three things we need to modernize our air traffic control system. People. Technology. And Innovation. They proudly employ thousands of America's best and brightest. And they're already solving many of America's toughest national security challenges. Peraton already works with the Department of War and, NASA. They are literally doing stuff by land, air, and even in outer space. Peraton is ready to provide America the air traffic control system we deserve. Safer. And more reliable. Head to https://Peraton.com/ATC to learn more. The future of air travel is here. Peraton. Lean Did you know that a 60 year old person has gained and lost hundreds of pounds over their lifetime? Doctors call it weight-cycling and it can be stressful and damaging to your body. If you find yourself gaining then losing weight every time you go on a diet then I have a solution for you, Lean. Lean helps maintain healthy blood sugar... IT helps control appetite and cravings... And IT helps burn FAT BY CONVERTING it to energy. And burning fat helps keep the weight off. So what are you weighting for, take control of your weight maintenance now by trying Lean. Just goto https://takelean.com and use code SEAN for 20% off your order. As we get more and more information on our food, medicine and our government services, we are able to make informed decision on our health and well being. Our government has become an over bloated bureaucracy machine in big food, big agriculture and big pharma. Today Dr. Robert Malone is here to inform us on the food we eat, the medicine we take and the guidelines we receive from organizations like the CDC. As the Trump administration overhauls government agencies like the FDA, Dr. Malone explains big agriculture put a stranglehold on our food supply. As more and more people become interested in regenerative farming, the government still has so much red tape and bureaucracy preventing a farm to table experience across the nation. As a member of the newly appointed vaccine advisory board under RFK Jr., Dr. Malone takes us back to operating warp speed and the covid vaccine rollout. As parents welcome their newborn into the world, are they being coerced to give their child the hepatitis B vaccine? Is this vaccine safe for our children? Dr. Robert Malone breaks it all down. Featuring: Dr. Robert Malone Physician. Scientist. Inventor https://www.malone.news/ FREE CONTENT FRIDAY: https://www.seanspicer.com/p/government-shutdown-over-healthcare ------------------------------------------------------------- 1️⃣ Subscribe and ring the bell for new videos: https://youtube.com/seanmspicer?sub_confirmation=1 2️⃣ Become a part of The Sean Spicer Show community: https://www.seanspicer.com/ 3️⃣ Listen to the full audio show on all platforms: Apple Podcasts: https://podcasts.apple.com/us/podcast/the-sean-spicer-show/id1701280578 Spotify: https://open.spotify.com/show/32od2cKHBAjhMBd9XntcUd iHeart: https://www.iheart.com/podcast/269-the-sean-spicer-show-120471641/ 4️⃣ Stay in touch with Sean on social media: Facebook: https://facebook.com/seanmspicer Twitter: https://twitter.com/seanspicer Instagram: https://instagram.com/seanmspicer/ 5️⃣ Follow The Sean Spicer Show on social media: Facebook: https://facebook.com/seanspicershow Twitter: https://twitter.com/seanspicershow Instagram: https://instagram.com/seanspicershow Learn more about your ad choices. Visit megaphone.fm/adchoices
“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53
Backlash comes amid the FDA's approval of another generic version of the abortion pill mifepristone. Meanwhile, a priest combats deforestation and works to revive agriculture in Uganda. And, Sixteen future priests were ordained deacons at St. Peter's Basilica.
Recent headlines warned pregnant women, “Don't take Tylenol.” But what does the science really say? In this episode of Healthy Looks Great on You, Dr. Vickie — an obstetrician who delivered 5,000 babies — unpacks the FDA's statement, the studies on acetaminophen and pregnancy, and the difference between correlation and causation. Learn what the evidence shows (and what it doesn't), why context matters, and how to balance risks without adding fear or guilt. Links: FDA Statement to Physicians The White House webpage Harvard study ABC interview with Dr. Makary Press conference video The Nurses Health Study Boston Birth Cohort Johns Hopkins statement Mt. Sinai study Swedish study in JAMA Subscribe to Healthy Looks Great on You podcast Learn more about Healthy Looks Great on You a lifestyle medicine podcast
Talking about condoms shouldn't feel awkward—it should feel empowering. In this episode, I sit down with Milla Impola, a sexual health educator and advocate with ONE® Condoms, to explore how pleasure, safety, and confidence all go hand-in-hand. From the FDA approval of condoms for anal sex to the innovation of over 50 custom-fit sizes, Milla is breaking down barriers and building better conversations about sex. 3 Things That Kick Ass In This Episode... Learn why fit, comfort, and lube matter for condom confidence and pleasure. How ONE® Condoms is making safer sex tools approachable and inclusive. DiscoverThe power of open, shame-free conversations about sexual health and boundaries. About Milla Milla Impola has a passion for increasing awareness and access to safer sex tools. One of Milla's proudest achievements is highlighting the FDA approval of ONE® and MyONE® Custom Fit condoms for anal sex—the first condoms in the U.S. to receive this designation. She has also played a key role in developing workshops and educational content that make condom use more approachable, including promoting MyONE® Custom Fit, a revolutionary brand that offers over 50 sizes for a better fit and increased comfort. Committed to fostering engaging and accessible sexual health conversations, Milla has helped shape innovative outreach programs, including the ONE® Condoms Ambassador Program and ONE® On Stage, which merge creativity, community, and education. Whether working with students, healthcare providers, or the public, her goal is to ensure that everyone has the knowledge and resources they need to protect and enjoy their sexual well-being. Connect With Milla Website Instagram Facebook LinkedIn Hey Guys, Check This Out! Are you a guy who keeps struggling to do that thing? You know the thing you keep telling yourself and others you're going to do, but never do? Then it's time to get real and figure out why. Join the 40 Plus: Gay Men Gay Talk, monthly chats. They happen the third Monday of each month at 5:00 pm Pacific - Learn More! Also, join our Facebook Community - 40 Plus: Gay Men, Gay Talk Community Break free of fears. Make bold moves. Live life without apologies
We're back and ready to rage hard and dive deep into this week's mosh pit of anti-abortion ass-wagging with y'all! Prepare thyself for a full breakdown of Pregnancy Justice's study on the shocking rise in the criminalization of pregnancy, abortion and miscarriage. Plus, hold onto your cheeks, ‘cause your Buzzkills are blowing Pam Bondi's latest scam wide open: hijacking a federal law meant to protect abortion providers and turning it against protesters. Party of free speech, our adorable asses. GUEST ROLL CALL Eliana Rodriguez, a Colombian student activist who met with Lizz in Colombia while speaking at the Human Rights Film Festival is in the house! Eliana's here to share the tactics and strategies she and her community used to bring Colombia from decriminalization to full legal abortion rights through the Green Wave Movement! PLUS! Bringing the hehes and the hahas is AAF ride or die comedian Jenny Zigrino! She pops by to dish on her fertility journey, the ish surrounding the Riyadh Comedy festival, and her new comedy tour called “Afterbirth.” Yes, we said afterbirth. Listen, you're just gonna have to tune in to find out, okay? Scared? Got Questions about the continued assault on your reproductive rights? THE FBK LINES ARE OPEN! Just call or text (201) 574-7402, leave your questions or concerns, and Lizz and Moji will pick a few to address on the pod! Times are heavy, but knowledge is power, y'all. We gotchu. OPERATION SAVE ABORTION: Check out our NEW Operation Save Abortion workshop, recorded a live from Netroots Nation 2025 that'll train you in coming for anti-abobo lawmakers, spotting and fighting against fake clinics, AND gears you up on how to help someone in a banned state access abortion. You can still join the 10,000+ womb warriors fighting the patriarchy by listening to past Operation Save Abortion trainings by clicking HERE for episodes, your toolkit, marching orders, and more. HOSTS:Lizz Winstead IG: @LizzWinstead Bluesky: @LizzWinstead.bsky.socialMoji Alawode-El IG: @Mojilocks Bluesky: @Mojilocks.bsky.social SPECIAL GUESTS:Eliana Rodriguez IG: @ElianaCRod Jenny Zigrino IG: @JennyZigrino TikTok: @JennyZigrinoComedy GUEST LINKS:Latin America's Green WaveINSTAGRAM: Causa Justa Por El AbortoINSTAGRAM: Karol Solís MencoJenny Zigrino's WebsiteJenny's LinktreeTICKETS: Jenny's Afterbirth TourJenny's PatreonJenny's Youtube NEWS DUMP:Anti-Abortion Leaders Blast Fda's Quiet Approval of a New Abortion PillWhy Men Need Abortion Healing — and How the Church Can HelpMichigan's Abortion Access Amendment Survives Right to Life SuitPope Leo XIV: Support for Death Penalty Is ‘Not Really Pro-Life'Hundreds of US Women Charged With Pregnancy-Related Crimes Since Fall of Roe EPISODE LINKS:10/5: Atlantic AnticWATCH: No One Asked You ScreeningsADOPT-A-CLINIC: Women's Health Center of MD Wishlist6 DEGREES: Bad Bunny Tapped for Super Bowl Halftime, Spotlighting Latin Pride and His Clashes With TrumpOperation Save AbortionExpose Fake ClinicsBUY AAF MERCH!EMAIL your abobo questions to The Feminist BuzzkillsAAF's Abortion-Themed Rage Playlist SHOULD I BE SCARED? Text or call us with the abortion news that is scaring you: (201) 574-7402 FOLLOW US:Listen to us ~ FBK Podcast Instagram ~ @AbortionFrontBluesky ~ @AbortionFrontTikTok ~ @AbortionFrontFacebook ~ @AbortionFrontYouTube ~ @AbortionAccessFrontTALK TO THE CHARLEY BOT FOR ABOBO OPTIONS & RESOURCES HERE!PATREON HERE! Support our work, get exclusive merch and more! DONATE TO AAF HERE!ACTIVIST CALENDAR HERE!VOLUNTEER WITH US HERE!ADOPT-A-CLINIC HERE!GET ABOBO PILLS FROM PLAN C PILLS HERE! When BS is poppin', we pop off! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
As Dalton sat in for Jim Schneider, here's a selection of stories he presented for the first half of the broadcast: --Last Sunday at least 4 victims died and multiple people were injured during a shooting at a Church of Jesus Christ of Latter Day Saints in Michigan. The assailant drove their vehicle through the front doors of the building, then got out and proceeded to shoot people. That suspect was later killed in a firefight with police. --A synagogue attack on Yom Kippur killed 2 in Manchester, England. --The U.N. added 68 companies to a blacklist they maintain are firms that do business with Jewish communities in Judea and Samaria. --Dalton read 9 signs that the world is preparing for war from Charisma Magazine. --Vladimir Putin has ordered the conscription of over 135,000 men by the end of 2025. --The FDA approved a new generic version of the abortion drug Mifepristone. --Planned Parenthood announced that their facility in Houston, Texas, the largest abortion facility in North America, is closing down.
Tariffs, drug pricing reform, a government shutdown and a major turnover at one of the world’s largest drugmakers all converged this week, leaving plenty to unpack for the industry as it heads into fall. Greater clarity on President Donald Trump’s tariff and pricing strategies has likely come as something of a relief for those companies operating in the U.S., but that news was tempered by a shutdown of the federal government on Wednesday. Meanwhile, big changes are likely on the way at GSK, whose longtime CEO Emma Walmsley is headed for the exit. In this week’s episode of "The Top Line," we break down some of the biggest stories across Fierce Pharma for the week—which may very well be some of the biggest stories of the year—touching on critical policy updates in the U.S., the furloughing of federal employees at agencies like the FDA and NIH and the imminent departure of GSK’s chief executive. Fierce Life Sciences’ Ben Adams sits down with Fierce Pharma's Fraiser Kansteiner to discuss the latest headlines and go over the key points from each major development that has played out. To learn more about the topics in this episode: FDA avoids the worst amid government shutdown, but new applications put on hold NIH research grinds to a halt as government shuts down Pfizer offers price concessions, $70B US outlay in Trump's 'most favored nation' push Trump's pharma tariffs on hold amid administration's effort to secure pricing concessions, industry investment: Stat GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels See omnystudio.com/listener for privacy information.
*The Farm Bill has expired. *The Trump Administration is expected to make an announcement regarding potential aid for farmers. *The nation's first bale of cotton raised over $24,000 for scholarships. *Some parts of the Texas High Plains are getting dry. *Cotton harvest continues across Texas. *The FDA has approved a drug to prevent and treat screwworms. *Fall is settling into East Texas. *The first generic BRD treatment for cattle has been approved by the FDA.
2025 ACC Scientific Statement on Inflammation & Cardiovascular Disease
Marcha del 2 de octubre deja destrozos y enfrentamientos en el Zócalo Arranca en Toluca la Feria y Festival Cultural del Alfeñique 2025La FDA aprueba en EU una nueva versión genérica de la píldora abortivaMás información en nuestro podcast
This is the 65th episode in my drug pronunciation series. In this episode, I divide Xarelto and rivaroxaban into syllables, tell you which syllables to emphasize, and share my sources. The written pronunciations are below and in the show notes on https://www.thepharmacistsvoice.com. Note: we don't cover pharmacology in this series. Just pronunciations. The FULL show notes are available at https://www.thepharmacistsvoice.com/podcast. Xarelto = zah-REL-toe zah, like the end of the word, “pizza” REL - like relish (which is a hot dog topping) toe - like the toes on your feet Emphasize REL Source for the written pronunciation = medication guide for Xarelto on the FDA's website (accessed Sept 30, 2025) Source for the spoken pronunciation = drugs.com or m-w.com (accessed 9-30-25) Rivaroxaban = RIV-a-ROX-a-ban or RIV-uh-ROCKS-uh-ban RIV, like river a, which is a short “A” sound (“uh”) ROX, like rocks in a riverbed a, which is that short “A” sound again (“uh”) ban, like something that is prohibited Emphasize RIV and ROX. ROX gets more emphasis than RIV. Source for the written pronunciation is USP Dictionary Online and MedlinePlus.gov Source for the spoken pronunciation = https://www.drugs.com/mtm/rivaroxaban.html Thank for listening to the 65th episode in my drug pronunciation series! If you'd like to recommend a drug name for this series, please reach out through the contact form on my website, thepharmacistsvoice.com. If you know someone who would like to learn how to say Xarelto and rivaroxaban, please share this episode with them. Subscribe for all future episodes. This podcast is on all major podcast players and YouTube. Popular links are below. ⬇️ Apple Podcasts https://apple.co/42yqXOG Spotify https://spoti.fi/3qAk3uY Amazon/Audible https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt ⭐️ Sign up for The Pharmacist's Voice ® monthly email newsletter! https://bit.ly/3AHJIaF Host Background: Kim Newlove has been an Ohio pharmacist since 2001 (BS Pharm, Chem Minor). Her experience includes hospital, retail, compounding, and behavioral health. She is also an author, voice actor (medical narrator and audiobook narrator), podcast host, and consultant (audio production and podcasting). Other episodes in this series The Pharmacist's Voice Podcast Episode 349, Pronunciation Series Episode 64 (acetaminophen) The Pharmacist's Voice Podcast Episode 348, Pronunciation Series Episode 63 (Welchol/colesevelam) The Pharmacist's Voice Podcast Episode 346, Pronunciation Series Episode 62 (valacyclovir) The Pharmacist's Voice Podcast Episode 343, Pronunciation Series Episode 61 (ubrogepant) The Pharmacist's Voice Podcast Episode 341, Pronunciation Series Episode 60 (topiramate) The Pharmacist's Voice Podcast Episode 339, Pronunciation Series Episode 59 (Suboxone) The Pharmacist's Voice Podcast Episode 337, Pronunciation Series Episode 58 (rosuvastatin) The Pharmacist's Voice Podcast Episode 335, Pronunciation Series Episode 57 (QVAR) The Pharmacist's Voice Podcast Episode 333, Pronunciation Series Episode 56 (pantoprazole) The Pharmacist's Voice Podcast Episode 330, Pronunciation Series Episode 55 (oxcarbazepine) The Pharmacist's Voice Podcast Episode 328, Pronunciation Series Episode 54 (nalmefene) The Pharmacist's Voice Podcast Episode 326, Pronunciation Series Episode 53 (Myrbetriq) The Pharmacist's Voice Podcast Episode 324, Pronunciation Series Episode 52 (liraglutide) The Pharmacist's Voice Podcast Episode 322, Pronunciation Series Episode 51 (ketamine) The Pharmacist's Voice Podcast Episode 320, Pronunciation Series Episode 50 (Jantoven) The Pharmacist's Voice Podcast Episode 318, Pronunciation Series Episode 49 (ipratropium) The Pharmacist's Voice Podcast Episode 316, Pronunciation Series Episode 48 (hyoscyamine) The Pharmacist's Voice Podcast Episode 313, Pronunciation Series Episode 47 (guaifenesin) The Pharmacist's Voice Podcast Episode 311, Pronunciation Series Episode 46 (fluticasone) The Pharmacist's Voice Podcast Episode 309, Pronunciation Series Episode 45 (empagliflozin) The Pharmacist's Voice Podcast Episode 307, Pronunciation Series Episode 44 (dapagliflozin) The Pharmacist's Voice Podcast Episode 304, Pronunciation Series Episode 43 (cetirizine) The Pharmacist's Voice Podcast Episode 302, Pronunciation Series Episode 42 (buspirone) The Pharmacist's Voice Podcast Episode 301, Pronunciation Series Episode 41 (azithromycin) The Pharmacist's Voice Podcast Episode 298, Pronunciation Series Episode 40 (umeclidinium) The Pharmacist's Voice Podcast Episode 296, Pronunciation Series Episode 39 (Januvia) The Pharmacist's Voice Podcast Episode 294, Pronunciation Series Episode 38 (Yasmin) The Pharmacist's Voice Podcast Episode 292, Pronunciation Series Episode 37 (Xanax, alprazolam) The Pharmacist's Voice Podcast Episode 290, Pronunciation Series Episode 36 (quetiapine) The Pharmacist's Voice Podcast Episode 287, pronunciation series ep 35 (bupropion) The Pharmacist's Voice Podcast Episode 285, pronunciation series ep 34 (fentanyl) The Pharmacist's Voice Podcast Ep 281, Pronunciation Series Ep 33 levothyroxine (Synthroid) The Pharmacist's Voice ® Podcast Ep 278, Pronunciation Series Ep 32 ondansetron (Zofran) The Pharmacist's Voice ® Podcast Episode 276, pronunciation series episode 31 (tocilizumab-aazg) The Pharmacist's Voice ® Podcast Episode 274, pronunciation series episode 30 (citalopram and escitalopram) The Pharmacist's Voice ® Podcast Episode 272, pronunciation series episode 29 (losartan) The Pharmacist's Voice Podcast Episode 269, pronunciation series episode 28 (tirzepatide) The Pharmacist's Voice Podcast Episode 267, pronunciation series episode 27 (atorvastatin) The Pharmacist's Voice Podcast Episode 265, pronunciation series episode 26 (omeprazole) The Pharmacist's Voice Podcast Episode 263, pronunciation series episode 25 (PDE-5 inhibitors) The Pharmacist's Voice Podcast Episode 259, pronunciation series episode 24 (ketorolac) The Pharmacist's Voice ® Podcast episode 254, pronunciation series episode 23 (Paxlovid) The Pharmacist's Voice ® Podcast episode 250, pronunciation series episode 22 (metformin/Glucophage) The Pharmacist's Voice Podcast ® episode 245, pronunciation series episode 21 (naltrexone/Vivitrol) The Pharmacist's Voice ® Podcast episode 240, pronunciation series episode 20 (levalbuterol) The Pharmacist's Voice ® Podcast episode 236, pronunciation series episode 19 (phentermine) The Pharmacist's Voice ® Podcast episode 228, pronunciation series episode 18 (ezetimibe) The Pharmacist's Voice ® Podcast episode 219, pronunciation series episode 17 (semaglutide) The Pharmacist's Voice ® Podcast episode 215, pronunciation series episode 16 (mifepristone and misoprostol) The Pharmacist's Voice ® Podcast episode 211, pronunciation series episode 15 (Humira®) The Pharmacist's Voice ® Podcast episode 202, pronunciation series episode 14 (SMZ-TMP) The Pharmacist's Voice ® Podcast episode 198, pronunciation series episode 13 (carisoprodol) The Pharmacist's Voice ® Podcast episode 194, pronunciation series episode 12 (tianeptine) The Pharmacist's Voice ® Podcast episode 188, pronunciation series episode 11 (insulin icodec) The Pharmacist's Voice ® Podcast episode 184, pronunciation series episode 10 (phenytoin and isotretinoin) The Pharmacist's Voice ® Podcast episode 180, pronunciation series episode 9 Apretude® (cabotegravir) The Pharmacist's Voice ® Podcast episode 177, pronunciation series episode 8 (metoprolol) The Pharmacist's Voice ® Podcast episode 164, pronunciation series episode 7 (levetiracetam) The Pharmacist's Voice ® Podcast episode 159, pronunciation series episode 6 (talimogene laherparepvec or T-VEC) The Pharmacist's Voice ® Podcast episode 155, pronunciation series episode 5 Trulicity® (dulaglutide) The Pharmacist's Voice ® Podcast episode 148, pronunciation series episode 4 Besponsa® (inotuzumab ozogamicin) The Pharmacist's Voice ® Podcast episode 142, pronunciation series episode 3 Zolmitriptan and Zokinvy The Pharmacist's Voice ® Podcast episode 138, pronunciation series episode 2 Molnupiravir and Taltz The Pharmacist's Voice ® Podcast episode 134, pronunciation series episode 1 Eszopiclone and Qulipta Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF ✅ LinkedIn Newsletter link https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ Get my FREE eBook and audiobook about podcasting ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Drug pronunciation course https://www.kimnewlove.com ✅ Podcasting course https://www.kimnewlove.com/podcasting ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with the same coach who helped me get started (Dave Jackson from The School of Podcasting)! **Affiliate Link - NEW 9-8-23** Thank you for listening to episode 350 of The Pharmacist's Voice ® Podcast. If you know someone who would like this episode, please share it with them!
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for September 28-October 4, 2025: FDA Approves Guselkumab (Tremfya) for Pediatric Plaque Psoriasis, Psoriatic Arthritis The FDA approved guselkumab as the first IL-23 inhibitor for children ≥6 years with moderate-to-severe plaque psoriasis or active psoriatic arthritis. FDA Approves Remibrutinib for Chronic Spontaneous Urticaria Remibrutinib, a selective BTK inhibitor, gained FDA approval for adults with chronic spontaneous urticaria based on sustained efficacy in phase 3 trials. Novo Nordisk Resubmits Insulin Icodec (Awiqli) Injection BLA for Type 2 Diabetes Novo Nordisk resubmitted its once-weekly insulin icodec BLA for type 2 diabetes after addressing prior FDA concerns. Novo Nordisk Submits Denecimig (Mim8) BLA for Hemophilia A Novo Nordisk filed a BLA for denecimig as prophylaxis for hemophilia A, supported by FRONTIER program data. VESALIUS-CV: Evolocumab (Repatha) Achieves Primary Endpoints in Patients with ASCVD Evolocumab reduced major cardiovascular events in ASCVD patients without prior MI or stroke in the phase 3 VESALIUS-CV trial.
New treatment approved for primary humoral immunodeficiency; eyedrops now available to improve near vision; Tremfya approval expanded to include pediatric plaque psoriasis, psoriatic arthritis; FDA fast tracks treatments for methamphetamine intoxication, Alzheimer disease.
The Republican-run government has shut down, Trump is using misinformation to blame Democrats, and Erin and Alyssa explain what's at stake. Then they dive into Ezra Klein's recent bad takeapalooza, on everything from Charlie Kirk's legacy to pro-life Democrats. And, of course, there's the latest Epstein files news, some races to watch in Virginia, and a big week for creeps, overall. They wrap up in the Sanity Corner with a discussion about their excitement for Aaron Sorkin's The Social Reckoning and a petty roast of Ivanka Trump's Instagram. Explaining the G.O.P.'s Misleading Talking Point on the Looming Shutdown (NYT 9/29)Ta-Nehisi Coates on Bridging Gaps vs. Drawing Lines (NYT 9/28)RFK Jr. launches FDA review of abortion pill (ABC News 9/24)Musk, Thiel and Bannon named in Epstein docs released by Dems (Axios 9/26)Elon Musk's Father Accused of Child Sexual Abuse (NYT 9/25)Money manager Howard Rubin detained in sex trafficking case after feds cite hitman threat (CNBC 9/26)Ryan Walters steps down as Oklahoma schools chief to lead anti-teachers union group (The 19th News 9/26)The State of Our Nation: Gauging Americans' political opinions in 2025 (The 19th* 9/25) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Abdul and Katelyn discuss the latest news in public health, which includes: Trump's $100,000 H1-B visa fee, which is could significantly hurt staffing in rural hospitals A new 100% tariff on certain imported brand-name drugs RFK Jr's announcement that the FDA is re-evaluating the abortion medication mifepristone A new scientific breakthrough that's giving hope to people with Huntington's Disease Then Abdul sits down with Dr. Aziz Rahman, an American physician who recently completed a medical mission in Gaza. Dr. Rahman offers a gripping account of the devastation in Gaza, and the heroic efforts of doctors serving there. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Work. Science Matters.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: Boll & Branch: For a limited time get 20% off your first set of sheets plus free shipping at BollAndBranch.com/AD. Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns. APHA: Listeners of this podcast get a 10% discount for the 2025 Annual Meeting and Expo using code: Dissected25.
Dr. Mary Tally Bowden is part of a growing movement to make ivermectin available without a prescription. She talks with Sharyl about efforts to take her down for prescrbing ivermectin during Covid, and how her lawsuit proved the FDA wrong.Order Sharyl's new bestselling book: “Follow the $cience.” Subscribe to my two podcasts: “The Sharyl Attkisson Podcast” and “Full Measure After Hours.” Leave a review, subscribe and share with your friends! Support independent journalism by visiting the new Sharyl Attkisson store.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, Darin exposes the toxic truth behind the billion-dollar anti-aging skincare industry. From mercury to PFOAs (the same chemical used in Teflon), many “miracle creams” and skin-lightening products marketed as beauty solutions are actually silently poisoning us. Darin breaks down the science, the loopholes in FDA regulation, and the real dangers of what's being absorbed through our skin — from hormone disruption to cancer and even risks to children. More importantly, he offers solutions: how to identify red flags, choose safe alternatives, and reclaim sovereignty over what you put on your body. What You'll Learn in This Episode: 00:00 – Welcome to SuperLife and the mission to live free from fatal conveniences 00:32 – The cookware sponsor shoutout and why toxic exposure starts in the kitchen 03:08 – Fatal Convenience focus: anti-aging skincare products and hidden toxins 04:39 – Why what you put on your skin is like ingesting it — the reality of transdermal absorption 05:40 – Mercury in cosmetics: how it destroys biology and hides under confusing chemical names 08:18 – PFOAs (Teflon chemicals) in skincare and why they're linked to cancer and hormone disruption 10:28 – The dangers extend beyond users — off-gassing mercury can affect families and children 11:29 – Even the FDA admits toxicity, yet products still end up on shelves 12:25 – Supplement sponsor shoutout: Manna Vitality for cellular renewal 14:20 – Mercury exposure risks for pregnant and nursing mothers, and infants 15:19 – Signs of mercury poisoning: irritability, tremors, depression, numbness 16:24 – Conflicts of interest and failures at FDA, EPA, USDA — why regulation isn't protecting you 17:26 – How to protect yourself: avoid “anti-aging” and “skin-lightening” labels, and do due diligence 18:20 – Brands exposed for cutting corners and why demand must shift 18:55 – Choosing botanical, organic, chemical-free products as the true path to health 19:26 – Final reminder: don't buy into marketing that preys on insecurity — sovereignty starts with awareness Thank You to Our Sponsors Our Place: Toxic-free, durable cookware that supports healthy cooking. Use code DARIN for 10% off at fromourplace.com. Manna Vitality: Go to mannavitality.com/ or use code DARIN20 for 20% off your order. Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences Key Takeaway “If you wouldn't eat it, don't put it on your skin. Mercury, PFOAs, and toxic chemicals in anti-aging creams are poisoning us — but when we choose botanical, organic, and safe alternatives, we reclaim our health and our sovereignty.”
What if the vision problems you'll face in your 70s are actually being determined by the choices you're making right now? We're constantly damaging our eyes without even realising it, through screen exposure, UV radiation, and nutritional deficiencies that silently accumulate over decades. The good news is, the FDA has approved its first-ever dry macular degeneration treatment in 2024, which reduces vision loss risk by 25%. Bonus: I'll also cover innovative therapies, essential nutrition, and lifestyle activities that can boost your eye health and prevent eye problems later on! Join the Ultimate Human VIP community for Gary Brecka's proven wellness protocols! https://bit.ly/4ai0Xwg Thank you to our partners H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP: SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP: JOIN AND GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW MASA CHIPS: 20% OFF FIRST ORDER: https://bit.ly/40LVY4y VANDY: “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij CARAWAY: “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS: “ULTIMATE” FOR 15% OFF: https://bit.ly/4inFfd7 RHO NUTRITION: “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC GENETIC TEST: https://bit.ly/3Yg1Uk9 Watch the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 Intro of Show 01:39 Latest Research on Vision Protection 02:24 How to Treat Dry Macular Degeneration 04:12 Laser Therapy for Glaucoma 06:15 Red Light Therapy for Dry Eyes 06:21 Essential Nutrients for Eye Health 10:11 Lifestyle Activities for Eye Health 12:49 Free Water Fasting Challenge The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices
WARNING: Sexually Explicit Discussion After practicing emergency medicine for decades, Dr. Elliot Justin noticed a critical gap in men's health care: There was no objective way to monitor erectile health, meaning that diagnoses and treatment prescriptions were made in the dark. Now the founder of FirmTech, Dr. Justin has created the world's first FDA-registered device for monitoring and improving men's erectile health, pleasure, and performance, while also providing insights into other areas of men's health, such as cardiovascular function. FirmTech recently won the Healthcare Startup Business Award from the Science & Engineering Health Technologies Alliance.
“Probably the most exciting thing I've seen in gene therapy over the last ten years is we now have a lot of tools for selective delivery, which will hopefully make treatments more safe and a lot more successful,” says Dr. Jessica Duis, a geneticist and pediatrician focused on the management of individuals with complex, rare disorders. Dr. Duis, who has worked on several gene therapies that are now approved or progressing through the accelerated approval pathway, is currently VP of Clinical Development at GondolaBio, a clinical-stage biopharmaceutical company focused on developing therapeutics for genetic diseases. As you'll learn in this Year of the Zebra episode with host Lindsey Smith, Dr. Duis is encouraged by other recent advances in genetic technology as well, and thinks momentum will grow as breakthrough treatments emerge. “I think we're hopefully going to continue to see companies that are working in rare disease be more successful and really drive how regulators think about making decisions in terms of bringing treatments to patients. I think we're at the tip of the iceberg in terms of the future of truly transformational therapies.” This wide ranging conversation also explores Dr. Duis' team approach to patient care, her work on clinical endpoints, the importance of patient communities, and her book series, Rare Siblings Stories.Mentioned in this episode:GondolaBioRareDiseaseDocElsevier Healthcare Hub on Rare DiseasesRare Sibling Stories If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
Cattle futures stepped lower Thursday, bowing to softer cash fed cattle prices and the continued seasonal decline in wholesale beef values. Some also suggested conditional FDA approval of an injectable from Zoetis for the prevention and control of New World screwworm might have been part of the pressure, speculating it might mean a quicker [...]
In today's episode, we had the pleasure of speaking with Anne Chiang, MD, PhD, and Stephen Liu, MD, about the FDA approval of lurbinectedin (Zepzelca) plus atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after frontline induction therapy with atezolizumab or atezolizumab and hyaluronidase, carboplatin, and etoposide. Chiang is an associate professor of medicine in the Section of Medical Oncology and the associate cancer center director of Clinical Initiatives at the Yale School of Medicine in New Haven, Connecticut. Dr Liu is an associate professor of medicine at Georgetown University, as well as the director of Thoracic Oncology and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. In our exclusive interview, Drs Chiang and Liu discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 IMforte trial (NCT05091567), and how the addition of this regimen in the ES-SCLC treatment paradigm may affect clinical practice.
Today at 3:15pm ET on The Jeff Dornik Show, I go live with Dr. Josef Witt‑Doerring, a board-certified psychiatrist and former FDA medical officer who's blowing the whistle on SSRIs. He's seen the inside of Big Pharma's psychiatric racket and is exposing how these so-called “antidepressants” are causing withdrawal, neurological damage, and long-term dependency—while tech censors silence the truth. What if the biggest mental health crisis isn't depression… but the drugs meant to “treat” it?Traditional healthcare is a government-backed scam to keep you broke and controlled. ShareRight is a healthshare built on freedom, transparency, and biblical values—no mandates, no woke coverage, just real people helping real people. Get your FREE quote and see how much you can save: https://jeffdornik.com/healthCatch The Jeff Dornik Show live every weekday at 1pm ET only on Rumble and Pickax, where free speech still reigns. https://rumble.com/c/jeffdornikSubscribe to my Pickax account today and get my hard-hitting, uncensored email newsletter delivered straight to your inbox.https://pickax.com/jeffdornikBig Tech is silencing truth while farming your data to feed the machine. That's why I built Pickax… a free speech platform that puts power back in your hands and your voice beyond their reach. Sign up today:https://pickax.com/?referralCode=y7wxvwq&refSource=copy
Alpha Picks from yesterday is WAY up. I showed you LIVE how I traded this one. Plus today I take you through finding Q4 winners using AI - Perplexity and Sidekick. It's a GREAT show. Here are the links to all the sales: TRENDSPIDER - The best charting software EVER - just over $50/month with my link
Obesity is often seen as a matter of willpower, but science tells a different story. My guest today, Dr. David Kessler—former FDA commissioner, lawyer, physician, and the man who took on Big Tobacco—explains why biology, not blame, drives our struggles with weight. On this episode of The Dr. Hyman Show, we talk about why weight struggles are so common today, what new drugs can and can't do, and how his new FDA petition targets one of the biggest culprits: processed refined carbs. Catch the full conversation on YouTube, or listen wherever you get your podcasts. [YOUTUBE THUMBNAIL] You'll learn: • How food companies use ingredients like processed refined carbs to make products irresistible • Why GLP-1 drugs help many lose weight—but can't fix the food environment driving the crisis • How belly fat fuels heart disease, diabetes, and cancer—and why ultraprocessed foods are a big part of the problem • Simple ways to break free from foods engineered to make you overeat • What Dr. Kessler's FDA petition could mean for limiting processed carbs in our food supply and improving our collective health Plus, here's a bonus: We've adapted Dr. Kelsser's petition into a free PDF guide—The Hard Truth About Processed Carbs—so you can see exactly how these ingredients affect your health…and why his FDA petition REALLY matters. Tune in, download the guide, and find out how you can be part of the solution. View Show Notes From This Episode Get Free Weekly Health Tips from Dr. Hyman https://drhyman.com/pages/picks?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Sign Up for Dr. Hyman's Weekly Longevity Journal https://drhyman.com/pages/longevity?utm_campaign=shownotes&utm_medium=banner&utm_source=podcast Join the 10-Day Detox to Reset Your Health https://drhyman.com/pages/10-day-detox Join the Hyman Hive for Expert Support and Real Results https://drhyman.com/pages/hyman-hive This episode is brought to you by Seed, Paleovalley, Function Health, Timeline and AirDoctor. Visit seed.com/hyman and use code 25HYMAN for 25% off your first month of Seed's DS-01® Daily Synbiotic. Get nutrient-dense, whole foods. Head to paleovalley.com/hyman for 15% off your first purchase. Join today at FunctionHealth.com/Mark and use code HYMAN100 to get $100 toward your membership. Support essential mitochondrial health and save 20% on Mitopure. Visit timeline.com/drhyman to get 20% off today. Get cleaner air. Right now, you can get up to $300 off at airdoctorpro.com/drhyman.
In this episode, I respond head-on to the claim that Tylenol causes autism. As a mom of a six-year-old with moderate-to-severe autism, I'm not a scientist—I'm just living this every day. I break down what the FDA, WHO, and researchers are actually saying about acetaminophen, why Tylenol is being singled out, and why the vaccine–autism myth refuses to die. But this isn't just science talk. I also dive into the raw reality of being a single mom raising a child with special needs. It's emotional, it's messy, it's unfiltered. I do lose my shit a little, so trigger warning for big feelings, hard truths, and some very loud honesty. We need nuance. We need humor. We need real conversations. This is mine. ✨ **THANK YOU TO OUR SPONSORS!**
On this episode of Vitality Radio, Jared takes a hard look at the cholesterol hypothesis and why it has failed to deliver true solutions for heart health. Instead of focusing on lowering cholesterol—a vital compound for hormones, brain function, and cellular integrity—he highlights the often-overlooked root cause: stiff, aging arteries. You'll learn how the blood vessels lose flexibility with age, stress, toxins, poor diet, and inactivity, and why this breakdown leads to high blood pressure and drives cardiovascular risk far more than cholesterol numbers alone. Jared explains the role of nitric oxide in reversing arterial aging and how natural boosters like beets, leafy greens, and amino acids support healthy nitric oxide production. This episode is about shifting the conversation: instead of suppressing what the body needs, learn how to encourage its own built-in repair and resilience mechanisms.Products:N.O. Cardio BoostVital D3/K2Ultimate Vitality MultiNutraBio Beet Root PowderSolaray Beet Root CapsulesNutraBio L-Citrulline PowderBlack Market Labs L-Citrulline PowderJust Ingredients Pre-Workout Solaray MycroBiome Formulas (Vitality Radio POW! Product of the Week 50% off with PROMO CODE: POW10)Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
© 2020-2025 Ivy Podcast Discovery LLC
